Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Sees Large Decrease in Short Interest

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the target of a large decline in short interest during the month of September. As of September 30th, there was short interest totalling 800 shares, a decline of 57.9% from the September 15th total of 1,900 shares. Based on an average trading volume of 8,400 shares, the short-interest ratio is presently 0.1 days.

Santen Pharmaceutical Price Performance

SNPHY remained flat at $11.76 on Friday. The company’s stock had a trading volume of 202 shares, compared to its average volume of 6,826. The firm’s fifty day moving average price is $12.22 and its 200-day moving average price is $10.94. Santen Pharmaceutical has a fifty-two week low of $8.31 and a fifty-two week high of $13.00.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.